These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 22703853)

  • 21. Multiple sclerosis treatment 2001.
    Rolak LA
    Neurol Clin; 2001 Feb; 19(1):107-18. PubMed ID: 11471759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
    Frohman EM; Racke M; van Den Noort S
    Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973
    [No Abstract]   [Full Text] [Related]  

  • 23. [Additional indicators of the assessment of efficacy of disease modifying drugs (preliminary results)].
    Iakushina TI; Lizhdvoĭ VIu; Vasilenko IA; Andriukhina OM; Kotov SV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):61-5. PubMed ID: 23528596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Current treatment of multiple sclerosis].
    Csépány T
    Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy.
    Freedman MS
    Eur J Neurol; 2014 Mar; 21(3):377-87, e18-20. PubMed ID: 24237582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
    J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?
    Chofflon M
    BioDrugs; 2005; 19(5):299-308. PubMed ID: 16207071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Multiple sclerosis: beyong first line therapies].
    Schluep M; Du Pasquier R
    Rev Med Suisse; 2012 May; 8(339):946-9. PubMed ID: 22675826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current treatment of autoimmune blistering diseases.
    Kasperkiewicz M; Schmidt E
    Curr Drug Discov Technol; 2009 Dec; 6(4):270-80. PubMed ID: 20025595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From defining antigens to new therapies in multiple sclerosis: honoring the contributions of Ruth Arnon and Michael Sela.
    Steinman L; Shoenfeld Y
    J Autoimmun; 2014 Nov; 54():1-7. PubMed ID: 25308417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New therapies in multiple sclerosis].
    Roggerone S; Chenevier F; Confavreux C; Vukusic S
    Rev Prat; 2012 Oct; 62(8):1057-60. PubMed ID: 23227596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?
    Castrop F; Kowarik MC; Albrecht H; Krause M; Haslinger B; Zimmer C; Berthele A; Hemmer B
    Neurology; 2012 Mar; 78(12):928-30. PubMed ID: 22402856
    [No Abstract]   [Full Text] [Related]  

  • 34. Treating immunobullous diseases: an update.
    Reynaert S; Black MM
    Dermatol Nurs; 2004 Feb; 16(1):29-34, 70. PubMed ID: 15022502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of ANCA-associated vasculitis: new therapies and a look at old entities.
    Zand L; Specks U; Sethi S; Fervenza FC
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):182-93. PubMed ID: 24602467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Refractory bullous pemphigoid with fatal outcome in a young patient.
    Cruz MJ; Santos P; Morais P; Barreto F; Azevedo F
    Int J Dermatol; 2013 May; 52(5):601-2. PubMed ID: 23590375
    [No Abstract]   [Full Text] [Related]  

  • 37. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.
    Kim MR; Kim HC; Kim SC
    Dermatology; 2011; 223(2):182-8. PubMed ID: 22025028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Newer versus older treatments for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B; Cohen JA
    Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunosuppressive therapy in children.
    Prasad R; Singh UK; Mittal R; Mishra OP
    J Indian Med Assoc; 2011 Feb; 109(2):101-2, 104-7. PubMed ID: 21888174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Escalating immunomodulatory therapy of multiple sclerosis. 1st supplement: December 2000].
    Multiple Sklerose-Therapie-Konsensus Gruppe (MSTKG)
    Nervenarzt; 2001 Feb; 72(2):150-7. PubMed ID: 11256151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.